Clinical and biomarker data highlight Klotho-associated findings across muscle performance, brain health, cognition, mood and healthy aging
- Brain Band™ clinical research reported approximately 12%–34% improvements in memory, 15%–30% in attention/cognitive measures, 18%–35% in mood-related measures and 15%–45% reductions in stress-related measures in selected datasets
- Selected Brain Band™-associated biomarker measurements demonstrated BDNF increases of approximately 133%–296% and Klotho increases reaching approximately 423%, supporting continued investigation of programmable bioelectric signaling for brain health and healthy aging
- BodStim™ electrical muscle stimulation research reported approximately 15%–25% improvements in strength, 10%–18% in VO₂/aerobic-performance measures, 8%–14% in lean-mass measures, 5%–12% reductions in body-fat measures, 15%–30% reductions in CRP/inflammatory measurements and Klotho increases ranging approximately 15%–230% in selected measurements and participant groups
HUNTINGTON BEACH, Calif. — September 19th, 2026 — Lionheart Health, Inc. (“Lionheart Health” or the “Company”), a regenerative health and longevity technology company developing bioelectric and multimodality technologies, today announced the presentation of positive clinical and biomarker data from its BodStim™ and Brain Band™ research programs at The Klotho Conference 2026, being held September 18–19 in Miami, Florida.
The presentations highlight Lionheart Health’s research into non-invasive bioelectric and neuromuscular stimulation approaches designed to influence endogenous biological pathways associated with Klotho, brain-derived neurotrophic factor (BDNF), muscle function, cognition and healthy aging.
The Klotho Conference brings together researchers, physicians, biotechnology innovators and other participants to discuss Klotho biology and emerging translational applications.
Presentation: Devices for Endogenous Klotho Stimulation and Results
Presenter: Howard J. Leonhardt
Founder, Executive Chairman & Co-CEO, Lionheart Health, Inc.
Session: Devices for Endogenous Klotho Stimulation and Results
Date: September 19, 2026
Time: 11:30 a.m.–12:00 p.m. EDT
Conference: The Klotho Conference 2026
Location: Miami, Florida
The presentation summarizes Lionheart Health’s work investigating programmable bioelectric signaling and neuromuscular electrical stimulation as potential non-invasive approaches for stimulating endogenous regenerative and longevity-associated pathways.
Brain Band™ Clinical Research
Lionheart Health’s Brain Band™ platform combines programmable, targeted bioelectric stimulation with a broader research strategy focused on neurological function and regenerative signaling.
Across Lionheart Health’s early clinical research and associated datasets, reported outcomes have included:
- Memory: approximately 12%–34% improvement
- Attention and cognitive performance: approximately 15%
–30% improvement - Mood-related measures: approximately 18%–
35% improvement - Stress-related measures: approximately 15%–
45% improvement - Participant response rates: approximately 80%–88%
on selected measures
Lionheart Health’s Brain Band™ research includes the DepressiStim™, MemoryStim™
The Company’s previously reported clinical research includes work conducted by the Dr. Juliana Tramontina Clinic Team in Porto Alegre, Brazil.
Brain Band™ Biomarker Findings
Lionheart Health is also investigating whether programmable bioelectric signaling can influence endogenous proteins and signaling pathways associated with neurological health and healthy aging.
In selected Lionheart Health-associated research and development measurements, reported biomarker findings have included:
- BDNF: approximately 133%–296% increases
- Klotho: increases reaching approximately 423% in selected measurements
BDNF is extensively studied for its relationship to neuronal survival, synaptic plasticity, learning and memory.
Klotho is a longevity-associated protein being studied for its potential relationships with aging, neurological health, muscle function, kidney biology and other aspects of human health.
These biomarker findings should be distinguished from clinical outcomes unless the biomarkers were specifically measured within the applicable clinical protocol.
BodStim™ Clinical and Functional Data
Lionheart Health’s BodStim™ program uses electrical muscle stimulation as part of the Company’s broader research into muscle health, physical performance, metabolic function and healthy aging.
Across selected research and development datasets, reported findings have included:
- Strength: approximately 15%–
25% improvement - VO₂/aerobic-performance measures: approximately 10%–
18% improvement - Lean mass: approximately 8%–14% improvement
- Body fat: approximately 5%–12% reduction
- CRP/inflammatory measurements: approximately 15
%–30% reduction - Klotho: approximately 15%–230% increases in selected measurements and participant groups
Clinical research in Brazil involving Dr. Carla Malguti and collaborators evaluated electrical muscle stimulation and related functional outcomes and has contributed to the continuing development of Lionheart Health’s BodStim™ research platform.
The Company is continuing to investigate the relationship between electrically stimulated muscle activity and circulating factors associated with muscle function, metabolism, inflammation and healthy aging.
A Muscle-Brain-Klotho Research Strategy
Lionheart Health’s development strategy is based in part on the hypothesis that muscle, brain and systemic aging biology are interconnected rather than isolated systems.
BodStim™ is being studied as a means of activating skeletal muscle and associated systemic signaling, while Brain Band™ is being developed to provide targeted programmable bioelectric stimulation directed toward neurological and regenerative pathways.
The Company is investigating these technologies both independently and as components of its broader Klotho-Up™ Healthspan Longevity research platform.
“Our objective is to understand whether we can use precisely programmed, non-invasive bioelectric stimulation to activate the body’s own regenerative and healthy-aging signaling systems,” said Howard J. Leonhardt, Founder, Executive Chairman and Co-CEO of Lionheart Health, Inc. “The BodStim and Brain Band data presented at The Klotho Conference provide encouraging evidence supporting continued clinical investigation of the relationship between bioelectric stimulation, muscle activation, brain health and endogenous Klotho signaling.”
Klotho-Up™ Study Results
Immediately following Lionheart Health’s device presentation scheduled to present:
“Klotho-Up Study Results for XPRIZE Healthspan”
September 19, 2026 — 12:05 p.m.–12:35 p.m. EDT
The Klotho-Up™ research program evaluates a broader multimodality healthspan strategy designed to measure outcomes across muscle, brain, immune and other biological systems.
The program incorporates extensive biomarker assessment alongside physical and cognitive measurements and is designed to help determine whether combinations of lifestyle optimization, muscle stimulation, bioelectric signaling and other investigational regenerative approaches can measurably influence biological pathways associated with healthy aging.
Lionheart Health at The Klotho Conference
The 2026 Klotho Conference is scheduled for September 18–19, 2026 in Miami, Florida and includes presentations addressing Klotho biology, muscle health, brain health, gene therapy, cellular delivery and emerging therapeutic applications.
Lionheart Health Founder Howard J. Leonhardt also serves as a Co-Chair of The Klotho Conference.
The conference program includes Dr. Makoto Kuro-o, discoverer of the klotho gene, as keynote speaker, along with researchers and biotechnology leaders working across Klotho science and translation.
Previous Lionheart Health Data Releases
Additional details regarding the underlying Brain Band™, BodStim™, Klotho-Up™ and related research programs, including previously released clinical and biomarker data, are available through Lionheart Longevity News.
The Company intends to continue expanding clinical evaluation of BodStim™, Brain Band™ and its broader Klotho-focused platform, including measurements of Klotho, BDNF, muscle performance, cognition, functional capacity, inflammation and other biomarkers associated with healthy aging.
About Lionheart Health, Inc.
Lionheart Health, Inc. is a regenerative health and longevity technology company developing a portfolio of bioelectric, neuromuscular stimulation and multimodality technologies designed to support healthspan, wellness and regenerative medicine research.
The Company’s development programs span muscle health, brain health, joint health, cardiovascular health, vision, sexual health, skin and hair regeneration, organ health and broader healthspan applications.
Lionheart Health’s research strategy includes programmable bioelectric signaling designed to influence endogenous regenerative proteins and biological pathways, including Klotho, BDNF, GDF10, SDF-1/CXCL12, PDGF, IGF-1, Sirtuins, Sestrins and other signaling factors.
For additional information and previous research announcements, visit Lionheart Longevity News.
Forward-Looking Statements
This press release contains forward-looking statements concerning Lionheart Health, Inc.’s research, product-development activities, clinical programs, intellectual property, planned studies and potential applications of its technologies. Forward-looking statements may include words such as “believe,” “intend,” “plan,” “expect,” “may,” “could,” “potential,” “designed,” “develop,” “investigate” and similar expressions.
Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Early-stage, pilot, observational, biomarker and investigational findings may not be confirmed in larger, randomized or controlled clinical studies and should not be interpreted as establishing safety or efficacy for unapproved indications.
Certain technologies and applications described herein remain investigational. References to biological pathways or biomarkers do not establish that a product prevents, treats or cures any disease. Lionheart Health undertakes no obligation to update forward-looking statements except as required by applicable law.
Company Contact
Lionheart Health, Inc.
Huntington Beach, California
Lionheart Longevity